FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending April 18, 2008
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons
I give below details of an increase in interests in Ordinary shares at a price
of GBP10.73 per share and Ordinary share ADRs at a price of $43.32 per ADR in
GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned
persons, following the re-investment of the dividend paid to shareholders on 10
April 2008.
Ordinary shares ADRs
Dr M M Slaoui 25.97
Mrs C E Bruck Slaoui 14.84
Mr EJ Gray 26.52
Mr D Learmouth 25.02
Mr W C Louv 14.19
Mr S M Werner 14.47
The Company and the above named persons were advised of this information on 18
April 2008.
This notification relates to a transaction notified in accordance with
Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
18 April 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: April 18, 2008 By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc